Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

被引:29
作者
Nelson, Winnie W. [1 ]
Wang, Li [2 ]
Baser, Onur [3 ,4 ]
Damaraju, Chandrasekharrao V. [5 ]
Schein, Jeffrey R. [1 ]
机构
[1] Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res HECOR, Raritan, NJ 08869 USA
[2] STATinMED Res, Plano, TX USA
[3] STATinMED Res, Ann Arbor, MI USA
[4] MEF Univ, Istanbul, Turkey
[5] Janssen Res & Dev LLC, Raritan, NJ USA
关键词
Atrial fibrillation; Clinical outcomes; International normalized ratio; USA; US veterans; Warfarin; RISK-FACTOR; ANTICOAGULATION CONTROL; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANT; PREDICTING STROKE; INTENSITY; HOSPITALS; QUALITY;
D O I
10.1007/s11096-014-0038-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although efficacious in stroke prevention in non-valvular atrial fibrillation, many warfarin patients are sub-optimally managed. Objective To evaluate the association of international normalized ratio control and clinical outcomes among new warfarin patients with non-valvular atrial fibrillation. Setting Adult non-valvular atrial fibrillation patients (a parts per thousand yen18 years) initiating warfarin treatment were selected from the US Veterans Health Administration dataset between 10/2007 and 9/2012. Method Valid international normalized ratio values were examined from the warfarin initiation date through the earlier of the first clinical outcome, end of warfarin exposure or death. Each patient contributed multiple in-range and out-of-range time periods. Main outcome measure The relative risk ratios of clinical outcomes associated with international normalized ratio control were estimated. Results 34,346 patients were included for analysis. During the warfarin exposure period, the incidence of events per 100 person-years was highest when patients had international normalized ratio < 2:13.66 for acute coronary syndrome; 10.30 for ischemic stroke; 2.93 for transient ischemic attack; 1.81 for systemic embolism; and 4.55 for major bleeding. Poisson regression confirmed that during periods with international normalized ratio < 2, patients were at increased risk of developing acute coronary syndrome (relative risk ratio: 7.9; 95 % confidence interval 6.9-9.1), ischemic stroke (relative risk ratio: 7.6; 95 % confidence interval 6.5-8.9), transient ischemic attack (relative risk ratio: 8.2; 95 % confidence interval 6.1-11.2), systemic embolism (relative risk ratio: 6.3; 95 % confidence interval 4.4-8.9) and major bleeding (relative risk ratio: 2.6; 95 % confidence interval 2.2-3.0). During time periods with international normalized ratio > 3, patients had significantly increased risk of major bleeding (relative risk ratio: 1.5; 95 % confidence interval 1.2-2.0). Conclusion In a Veterans Health Administration non-valvular atrial fibrillation population, exposure to out-of-range international normalized ratio values was associated with significantly increased risk of adverse clinical outcomes.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [31] Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation
    Wu, Shanshan
    Xie, Shuo
    Xu, Yingjie
    Que, Dongdong
    Yau, Tung On
    Wang, Lizi
    Huang, Yuanping
    JOURNAL OF CLINICAL NURSING, 2019, 28 (9-10) : 1839 - 1846
  • [32] Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis
    Ali, Ali
    Bailey, Claire
    Abdelhafiz, Ahmed H.
    AGE AND AGEING, 2012, 41 (05) : 681 - 684
  • [33] Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study
    Naganuma, Miyoko
    Shiga, Tsuyoshi
    Sato, Kumi
    Murasaki, Kagari
    Hashiguchi, Masayuki
    Mochizuki, Mayumi
    Hagiwara, Nobuhisa
    THROMBOSIS RESEARCH, 2012, 130 (01) : 21 - 26
  • [34] Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
    Norby, Faye L.
    Bengtson, Lindsay G. S.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Chamberlain, Alanna M.
    Rapson, Ian
    Alonso, Alvaro
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [35] Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view
    Xie, Lin
    Vo, Lien
    Keshishian, Allison
    Price, Kwanza
    Singh, Prianka
    Mardekian, Jack
    Bruno, Amanda
    Baser, Onur
    Kim, Jully
    Tan, Wilson
    Trocio, Jeffrey
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (08) : 769 - 776
  • [36] Incidence and predictors of clinically significant renal function decline among Asian non-valvular atrial fibrillation patients on warfarin
    Hock Peng Koh
    Jiaa Yinn Tang
    Szu Lynn Tay
    Jivanraj R. Nagarajah
    Pradeep Kumar Nair Arumugam
    Discover Medicine, 2 (1):
  • [37] Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
    Chan, Yi-Hsin
    Yeh, Yung-Hsin
    Tu, Hui-Tzu
    Kuo, Chi-Tai
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    See, Lai-Chu
    ONCOTARGET, 2017, 8 (58) : 98898 - 98917
  • [38] Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation
    Suzuki, Tsuyoshi
    Shiga, Tsuyoshi
    Omori, Hisako
    Tatsumi, Fujio
    Nishimura, Katsuji
    Hagiwara, Nobuhisa
    JOURNAL OF CARDIOLOGY, 2017, 70 (3-4) : 238 - 243
  • [39] Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China
    Xiang, Xiao
    Cao, Yaying
    Sun, Kexin
    Song, Jing
    Tian, Yaohua
    Yin, Qiongzhou
    Juan, Juan
    Hu, Yonghua
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 255 - 261
  • [40] Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D
    Welander, Frida
    Renlund, Henrik
    Dimeny, Emoke
    Holmberg, Henrik
    Sjalander, Anders
    CLINICAL KIDNEY JOURNAL, 2022, 15 (06) : 1169 - 1178